The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer: The SOFT study.
Daisuke Takahari
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Yasuhide Yamada
Consultant or Advisory Role - Taiho Pharmaceutical
Hiroshi Matsumoto
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Hideo Baba
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Chugai Pharma; Pfizer; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Pfizer; Taiho Pharmaceutical; Yakult
Kazuhiro Yoshida
Consultant or Advisory Role - Chugai Pharma; Taiho Pharmaceutical
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Pfizer; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Kyowa Hakko Kirin; Pfizer; Taiho Pharmaceutical; Yakult
Masato Nakamura
Honoraria - Chugai Pharma; Pfizer; Taiho Pharmaceutical; Yakult
Motoki Yoshida
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Yakult
Shigeyoshi Iwamoto
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Yasutaka Takinishi
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Yakult
Yuh Sakata
Consultant or Advisory Role - Taiho Pharmaceutical; Yakult
Honoraria - Taiho Pharmaceutical; Yakult
Satoshi Morita
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Yakult
Yasuhiro Shimada
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Taiho Pharmaceutical
Yoshito Komatsu
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Pfizer; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Pfizer; Taiho Pharmaceutical; Yakult
Yasutsuna Sasaki
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Yakult
Taroh Satoh
Consultant or Advisory Role - Chugai Pharma; Taiho Pharmaceutical
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Pfizer; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Yakult
Keiichi Takahashi
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Hideyuki Mishima
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Yakult
Kei Muro
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Pfizer; Taiho Pharmaceutical; Yakult
Masahiko Watanabe
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Chugai Pharma; Pfizer; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Pfizer; Taiho Pharmaceutical; Yakult
Kenichi Sugihara
Consultant or Advisory Role - Chugai Pharma; Merck; Taiho Pharmaceutical; Takeda; Yakult
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kaken Pharmaceutical; Kyowa Hakko Kirin; Merck Serono; Otsuka; Taiho Pharmaceutical; Takeda; Wyeth; Yakult